BUZZ — Street View: J&J's macro troubles to pass, brokerages say
* Johnson & Johnson on Tuesday missed Wall Street expectations for sales at its medical devices business, hurt by geopolitical issues including the Middle East conflict * On average, 26 analysts rate stock "buy"; their median PT is $280 - data compiled by LSEG Focus On 2027 * Raymond James ("outperform," PT: $278) says